Virksomhedsform
Anpartsselskab
Etableret
1999
Størrelse
Store
Ansatte
719
Omsætning
1.026 MDKK
Bruttofortj.
175 MDKK
Primært resultat (EBIT)
82 MDKK
Årets resultat
61 MDKK
Egenkapital
654 MDKK
annonce

Flere nøgletal og analyser?

Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!

Rang Årets resultat

Rang i branche
14/1.796
"Top 10%"
Rang i Danmark
2.487/350.505
"Top 10%"

Direktion top 3

Bestyrelse top 3

Anders Meier 2Bestyrelsesformand
Ieva Blekte Tackie 2Bestyrelsesmedlem
Lene Klejs Stuhr 2Bestyrelsesmedlem

Legale ejere top 3

Tegningsregler

Selskabet tegnes af en direktør eller af et bestyrelsesmedlem eller af den samlede bestyrelse

Stamoplysninger baseret på CVR

NavnAgilent Technologies Denmark Aps
BinavneProzyme Europe Aps, Seahorse Bioscience Europe Aps Vis mere
CVR21852902
AdresseProduktionsvej 42, 2600 Glostrup
BrancheEngroshandel med andre maskiner og andet udstyr [466400]
Etableret01-07-1999 (25 år)
Første regnskabsperiode01-07-1999 til 31-10-2000
VirksomhedsformAnpartsselskab
Antal ansatte720 (årsværk:712)
ReklamebeskyttelseJa
RevisorBdo Statsautoriseret Revisionsaktieselskab siden 07-10-2019
Regnskabsperiode01-11 til 31-10
Selskabskapital5.000.001 DKK
5.000.000 DKK (29-10-1999 - 31-10-2016)
500.000 DKK (01-07-1999 - 28-10-1999)
Vedtægter seneste05-08-2019

Medlem af brancherne

Formål

Selskabets formål er at drive virksomhed med handel, fabrikation og investering samt anden virksomhed, der står i forbindelse hermed.

Regnskab

 202420232022
Valuta/enhed000' DKK000' DKK000' DKK
Omsætning
1.025.827
+7%
956.183
-1%
964.729
-9%
Bruttofortjeneste
174.828
+32%
132.500
-8%
144.480
+24%
Årets resultat
61.380
+196%
20.718
-36%
32.466
+20%
Egenkapital
654.253
+10%
592.873
+4%
572.155
+6%
Balance
868.813
+2%
848.308
+6%
797.672
-5%

Ledelsesberetning sammendrag

Beskrivelse af virksomhedens væsentligste aktiviteter
Principal activities
Agilent Technologies Denmark ApS, hereinafter referred to as “company”, operates as a reseller of products/services covering life sciences, diagnostics and applied chemicals markets. A major part of the products/services range is purchased from group companies within and outside of Denmark. The company is also engaged in the business of rendering contract manufacturing, research & development, product marketing and administrative services to group companies outside of Denmark. There is no significant change in the company’s activities or financial and economic conditions.
Beskrivelse af udviklingen i virksomhedens aktiviteter og økonomiske forhold
Development in activities and financial and economic position
The management continues to work towards achieving operational efficiencies through process realignment and development. The company together with its group companies continues to pursue new products, markets and opportunities. During FY24, the Agilent group witnessed changes in its executive leadership and the new team announced initiatives to better position Agilent in the continuously evolving market landscape. The past year also brought in new macroeconomic and industry specific challenges to our markets. The company implemented measures including cost effectiveness, customer centricity and process simplifications to achieve sustainable profitable growth.
Omtale af betydningsfulde hændelser, som er indtruffet efter regnskabsårets afslutning
Significant events after the end of the financial year
Apart from the abovementioned developments, the Board of Directors and Executive Management are not aware of any event after 31st October 2024 that may have a material impact on the company’s financial position.
Beskrivelse af virksomhedens forventede udvikling
Future expectations
The management recognizes the challenges of the current economic environment but expects a profitable fiscal ahead. The corporate guidance for worldwide Agilent group earnings is publicly available in our first quarter earnings report released on 26th Feb 2025. It is Agilent’s group policy to release estimates of future earnings at a consolidated worldwide level. With respect to the Denmark based company the revenues are estimated to be in a broad range from DKK 900M to 1,100M based on past business trends. The Agilent group expects that market conditions will continue to be challenging and possibly also be affected by increasing uncertainties in global supply chains and tariff concerns. Consequently, the net profits are broadly estimated to be in the range of DKK 40-60M.
Generalforsamlingsdato: 29-04-2025

Kort